IMMUNOME INC (IMNM:NASDAQ)
$23.35 -0.82 (-3.3926%)
Analysed IMMUNOME INC (IMNM:NASDAQ) News Sources
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
12-05-2026
yahoo.com
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
18-05-2026
yahoo.com
Barclays initiates oncology-focused biotechs with positive outlook
28-05-2026
yahoo.com
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
30-05-2026
yahoo.com
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?
05-06-2026
yahoo.com
4 Biotech Stocks Investors Should Watch in 2026
05-06-2026
yahoo.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
11-06-2026
yahoo.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07-07-2026
yahoo.com
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
08-07-2026
yahoo.com
Immunome Stock Up 32% in a Month: Here's What You Should Know
10-07-2026
yahoo.com
What is the current price of IMMUNOME INC (IMNM:NASDAQ)?
The current price of IMMUNOME INC (IMNM:NASDAQ) is $23.35.
IMMUNOME INC (IMNM:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNOME INC (IMNM:NASDAQ) since the previous trading day is $-0.82.
IMMUNOME INC (IMNM:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNOME INC (IMNM:NASDAQ) since the previous trading day is -3.3926%.
What is the most recent average sentiment score for IMMUNOME INC (IMNM:NASDAQ)?
The most recent average sentiment score for IMMUNOME INC (IMNM:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for IMMUNOME INC (IMNM:NASDAQ)?
The most recent sentiment for IMMUNOME INC (IMNM:NASDAQ) is .
SEC-8K** Filing Available For IMMUNOME INC (IMNM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.